Association between insulin-like growth factor-1 receptor (IGF1R) negativity and poor prognosis in a cohort of women with primary breast cancer.

Kristina Aaltonen; Ann Rosendahl; Hans Olsson; Per Malmström; Linda Werner Hartman; Mårten Fernö

doi:10.1186/1471-2407-14-794

Association between insulin-like growth factor-1 receptor (IGF1R) negativity and poor prognosis in a cohort of women with primary breast cancer.

Kristina Aaltonen, Ann Rosendahl, Hans Olsson, Per Malmström, Linda Werner Hartman, Mårten Fernö

Research output: Contribution to journal › Article › peer-review

178 Downloads (Pure)

Abstract

Resistance towards endocrine therapy is a great concern in breast cancer treatment and may partly be explained by the activation of compensatory signaling pathways. The aim of the present study was to investigate if the insulin-like growth factor-1 receptor (IGF1R) signaling pathway was activated or deregulated in breast cancer patients and to explore if any of the markers were prognostic, with or without adjuvant tamoxifen. This signaling pathway has been suggested to cause estrogen independent cell growth and thus contribute to resistance to endocrine treatment in estrogen receptor (ER) positive breast cancer.

Original language	English
Article number	794
Journal	BMC Cancer
Volume	14
DOIs	https://doi.org/10.1186/1471-2407-14-794
Publication status	Published - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Subject classification (UKÄ)

Cancer and Oncology

Access to Document

10.1186/1471-2407-14-794

BMC_Aaltonen_et_al

http://www.ncbi.nlm.nih.gov/pubmed/25362932?dopt=Abstract

Cite this

@article{a96728c4f46944df90d5598b0e200400,

title = "Association between insulin-like growth factor-1 receptor (IGF1R) negativity and poor prognosis in a cohort of women with primary breast cancer.",

abstract = "Resistance towards endocrine therapy is a great concern in breast cancer treatment and may partly be explained by the activation of compensatory signaling pathways. The aim of the present study was to investigate if the insulin-like growth factor-1 receptor (IGF1R) signaling pathway was activated or deregulated in breast cancer patients and to explore if any of the markers were prognostic, with or without adjuvant tamoxifen. This signaling pathway has been suggested to cause estrogen independent cell growth and thus contribute to resistance to endocrine treatment in estrogen receptor (ER) positive breast cancer.",

author = "Kristina Aaltonen and Ann Rosendahl and Hans Olsson and Per Malmstr{\"o}m and \{Werner Hartman\}, Linda and M{\aa}rten Fern{\"o}",

year = "2014",

doi = "10.1186/1471-2407-14-794",

language = "English",

volume = "14",

journal = "BMC Cancer",

issn = "1471-2407",

publisher = "BioMed Central (BMC)",

}

TY - JOUR

T1 - Association between insulin-like growth factor-1 receptor (IGF1R) negativity and poor prognosis in a cohort of women with primary breast cancer.

AU - Aaltonen, Kristina

AU - Rosendahl, Ann

AU - Olsson, Hans

AU - Malmström, Per

AU - Werner Hartman, Linda

AU - Fernö, Mårten

PY - 2014

Y1 - 2014

N2 - Resistance towards endocrine therapy is a great concern in breast cancer treatment and may partly be explained by the activation of compensatory signaling pathways. The aim of the present study was to investigate if the insulin-like growth factor-1 receptor (IGF1R) signaling pathway was activated or deregulated in breast cancer patients and to explore if any of the markers were prognostic, with or without adjuvant tamoxifen. This signaling pathway has been suggested to cause estrogen independent cell growth and thus contribute to resistance to endocrine treatment in estrogen receptor (ER) positive breast cancer.

AB - Resistance towards endocrine therapy is a great concern in breast cancer treatment and may partly be explained by the activation of compensatory signaling pathways. The aim of the present study was to investigate if the insulin-like growth factor-1 receptor (IGF1R) signaling pathway was activated or deregulated in breast cancer patients and to explore if any of the markers were prognostic, with or without adjuvant tamoxifen. This signaling pathway has been suggested to cause estrogen independent cell growth and thus contribute to resistance to endocrine treatment in estrogen receptor (ER) positive breast cancer.

UR - https://www.scopus.com/pages/publications/84920811592

U2 - 10.1186/1471-2407-14-794

DO - 10.1186/1471-2407-14-794

M3 - Article

C2 - 25362932

SN - 1471-2407

VL - 14

JO - BMC Cancer

JF - BMC Cancer

M1 - 794

ER -

Association between insulin-like growth factor-1 receptor (IGF1R) negativity and poor prognosis in a cohort of women with primary breast cancer.

Abstract

UN SDGs

Subject classification (UKÄ)

Access to Document

Other files and links

Fingerprint

Cite this